Skip to search formSkip to main contentSkip to account menu

vedolizumab 300 MG Injection [Entyvio]

Known as: Entyvio 300 MG Injection, VEDOLIZUMAB 300 mg in 5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Entyvio] 
National Institutes of Health

Related topics

Related topics

9 relations
Arginine hydrochlorideEntyvioHistidineInjection

Broader (1)

vedolizumab Injection [Entyvio]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model.
From the regulatory point of view a strong link between an animal model and human pharmacodynamics of biological drugs is very… 
2019
2019
Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
Çekiç Ş, Özgür T, Karalı Y, Özkan T, Kılıç SŞ. Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe… 
2018
2018
Nervenschäden durch orale Vitamin-B12-Gabe verhindern
2018
2018
Opioide im direkten Vergleich
  • R. Fath
  • MMW - Fortschritte der Medizin
  • 2018
  • Corpus ID: 80809071
2018
2018
Frühe Therapie zur Vermeidung von Fisteln
  • R. Fath
  • MMW - Fortschritte der Medizin
  • 2018
  • Corpus ID: 81143579
Höhere Remissionsraten Dies zeigen retrospektive Datenanalysen zum Einsatz des α4β7-Integrin-Antagonisten Vedolizumab (Entyvio… 
2016
2016
Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use
Vedolizumab (Entyvio™), a humanized monoclonal antibody α4β7 integrin-receptor antagonist with gut-selective effects, is a useful… 
2016
2016
Erratum to: Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use
2016
2016
P-126 PTG-100, An Oral Peptide Antagonist of Integrin &agr;4&bgr;7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models
Background:The &agr;4&bgr;7 integrin is a clinically validated target in inflammatory bowel disease (IBD). Vedolizumab (Entyvio… 
Review
2014
Review
2014
Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Vedolizumab (Entyvio™) is a humanized monoclonal antibody α4β7 integrin-receptor antagonist indicated for the treatment of adult… 
2014
2014
New humanised monoclonal antibody vedolizumab (Entyvio ® ) becomes the first gut-selective treatment licensed for moderately to severely active Ulcerative Colitis and Crohn's Disease
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)